Answer
Spikevax JN.1 (mRNA-1273.167) stimulates both T-cell and B-cell responses to generate neutralising antibodies, which may contribute to protection against COVID-19.
Sources for this answer
- Spikevax JN.1 0.1 mg/mL dispersion for injectionModerna Biotech Distributor UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 4Document updated
Sources checked